公开(公告)号：US09676802B2

公开(公告)日：2017-06-13

申请号：US14254265

申请日：2014-04-16

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Xiaowen Peng ,  Zhigang Chen ,  Yat Sun Or

IPC: A01N43/56 ,  A61K31/415 ,  C07F9/6561 ,  A61K31/426 ,  C07D498/08 ,  C07D498/18 ,  C07D519/00 ,  A61K38/21 ,  A61K31/13 ,  A61K31/7056 ,  A61K38/55 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06

CPC classification number: C07F9/65616 ,  A61K31/13 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/21 ,  A61K38/55 ,  A61K45/06 ,  C07D498/08 ,  C07D498/18 ,  C07D519/00 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—Z—W  (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20160289212A1

公开(公告)日：2016-10-06

申请号：US15088517

申请日：2016-04-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Wei Li ,  Jorden Kass ,  Xuri Gao ,  Xiaowen Peng ,  Meizhong Jin ,  Yat Sun Or

IPC: C07D401/12 ,  A61K31/695 ,  A61K45/06 ,  A61K31/454 ,  C07D409/14 ,  C07D403/12 ,  A61K31/55 ,  C07D233/64 ,  A61K31/4164 ,  C07D413/12 ,  A61K31/5377 ,  A61K31/496 ,  C07D417/14 ,  C07D413/14 ,  C07D401/14 ,  A61K31/553 ,  C07F7/18

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R1  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 其抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的HBV生命周期的功能，并且也可用作抗病毒剂。 本发明还涉及包含用于给患有HBV感染的受试者的上述化合物的药物组合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。

公开(公告)号：US20160222034A1

公开(公告)日：2016-08-04

申请号：US15007567

申请日：2016-01-27

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Xiaowen Peng ,  Xuri Gao ,  Yat Sun Or ,  Zachary Kevin Sweeney

IPC: C07D519/00 ,  A61K31/4188 ,  A61K45/06 ,  A61K31/427 ,  C07D491/107 ,  A61K31/4184

CPC classification number: C07D519/00 ,  A61K31/13 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/427 ,  A61K31/7056 ,  A61K38/19 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  A61K45/06 ,  C07D403/14 ,  C07D405/14 ,  C07D491/107 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式（I）的化合物及其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20140341851A1

公开(公告)日：2014-11-20

申请号：US14245001

申请日：2014-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： YAO-LING QIU ,  Ce Wang ,  Xiaowen Peng ,  Hui Cao ,  Lu Ying ,  Xuri Gao ,  Bin Wang ,  Yat Sun Or

IPC: C07D498/10 ,  A61K31/4184 ,  C07D401/14 ,  A61K31/444 ,  C07D405/14 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/496 ,  C07F9/6506 ,  A61K31/675 ,  C07D487/08 ,  A61K31/506 ,  C07D409/14 ,  C07D413/14 ,  A61K31/422 ,  C07D491/107 ,  A61K31/517 ,  C07D417/14 ,  A61K45/06 ,  C07D403/14

CPC classification number: C07D498/10 ,  A61K31/13 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/427 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/19 ,  A61K38/21 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/08 ,  C07D491/107 ,  C07F9/65583 ,  A61K2300/00 ,  A61K39/12

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20140308243A1

公开(公告)日：2014-10-16

申请号：US14254265

申请日：2014-04-16

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Xiaowen Peng ,  Zhigang Chen ,  Yat Sun Or

IPC: C07F9/6561 ,  A61K31/4188 ,  A61K45/06 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/427 ,  A61K31/422 ,  A61K31/675 ,  A61K31/4709 ,  A61K31/428 ,  A61K31/4245 ,  A61K31/4196 ,  A61K31/506 ,  C07D498/18

CPC classification number: C07F9/65616 ,  A61K31/13 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/21 ,  A61K38/55 ,  A61K45/06 ,  C07D498/08 ,  C07D498/18 ,  C07D519/00 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—Z—W  (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式（I）的化合物及其药学上可接受的盐，酯或前药：抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的Q-G-A-L-B-Z-W（I） 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20140187793A1

公开(公告)日：2014-07-03

申请号：US14082406

申请日：2013-11-18

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xiaowen Peng ,  In Jong Kim ,  Hui Cao ,  Datong Tang ,  Yat Sun Or ,  Guoqiang Wang ,  Guoyou Xu

IPC: C07D209/54

CPC classification number: C07D209/54

Abstract: The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (Ia), (Ib) and (Ic):

Abstract translation: 本发明一般涉及一种制备5-氮杂螺[2.4]庚烷-6-羧酸及其衍生物的改进方法，其在合成生物活性分子中是有用的中间体，特别是在合成肝素C病毒NS5A抑制剂 。 特别地，本发明涉及制备式（Ia），（Ib）和（Ic）化合物的方法和中间体：

公开(公告)号：US12145942B2

公开(公告)日：2024-11-19

申请号：US18130641

申请日：2023-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Jiajun Zhang ,  Xuechao Xing ,  Matthew C. Rhodes ,  Xuri Gao ,  Wei Li ,  Yat Sun Or

IPC: C07D487/10

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230241012A1

公开(公告)日：2023-08-03

申请号：US18101258

申请日：2023-01-25

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Jorden Kass ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Byung-Chul Suh ,  Yat Sun Or

IPC: A61K31/167 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  A61K31/401 ,  C07C303/00 ,  C07C317/44

CPC classification number: A61K31/167 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  A61K31/401 ,  C07C303/00 ,  C07C317/44 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:


X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11384090B2

公开(公告)日：2022-07-12

申请号：US17479244

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Yong He ,  Xuri Gao ,  Jun Ma ,  Xuechao Xing ,  Hui Cao ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210230176A1

公开(公告)日：2021-07-29

申请号：US17143326

申请日：2021-01-07

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D493/08 ,  C07C317/44 ,  C07C323/62 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/00 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C323/42 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.